Hers LegitScript and Accreditation Status: Is Hers a Legitimate Telehealth Platform?

What LegitScript Certification Actually Means for Hers

LegitScript certification is the clearest independent signal that an online pharmacy or telehealth platform meets baseline legal and safety standards. Hers holds LegitScript certification for its pharmacy operations, meaning its dispensing practices cleared a multi-point review covering prescription validity, licensure, and drug safety policies.

How LegitScript Reviews Online Pharmacies

LegitScript is a third-party verification company whose standards are used by Google, Microsoft Bing, and major payment processors to decide whether an online pharmacy can advertise or operate on their platforms. Their certification program requires applicants to demonstrate valid pharmacy licensure in every state they serve, documented prescriber-patient relationships, and compliance with federal drug laws including the Controlled Substances Act and the Ryan Haight Online Pharmacy Consumer Protection Act.

The program is not a government accreditation. It does not replace DEA registration, state pharmacy board licensure, or FDA oversight. Think of it as a rigorous background check rather than a federal seal of approval.

What Hers' Certification Covers

Hers operates its own pharmacy network and partners with third-party compounding pharmacies. The LegitScript certification applies to the online pharmacy storefront, verifying that prescriptions are issued by licensed clinicians before any medication ships. This matters for patients ordering items like topical minoxidil, oral contraceptives, or branded GLP-1 agents.

Compounded semaglutide and other compounded peptides, however, occupy a separate regulatory space. Compounding pharmacies registered as 503A (patient-specific) or 503B (outsourcing facility) under the FDA's framework operate under distinct rules that LegitScript certification does not fully address. Patients should verify that any compounding pharmacy Hers uses holds active 503B registration or PCAB accreditation independently.

Verifying Status Yourself

You can search any online pharmacy at LegitScript.com's public lookup at any time. Status can change if a platform fails to renew its certification or if a compliance violation is found. Cross-referencing Hers' current status at the time you enroll takes about 30 seconds.

Is Hers a Legitimate Telehealth Company? Regulatory and Legal Standing

Hers (operated by Hims, Inc. / Hims & Hers Health, Inc., ticker: HIMS) is a publicly traded company listed on the New York Stock Exchange, which subjects it to SEC disclosure requirements and regular financial audits. That corporate structure does not guarantee clinical quality, but it does mean the company is not an anonymous offshore pill mill.

State Medical Board and Pharmacy Licensure

Telehealth platforms must employ or contract with clinicians licensed in the patient's state of residence. Hers states that its provider network includes physicians, nurse practitioners, and physician assistants licensed across all 50 states. Prescriptions for controlled substances require separate verification under the DEA's telemedicine rules, which tightened significantly after the end of COVID-era flexibility in 2024.

The DEA interim final rule on telemedicine prescribing of controlled substances requires that patients have at least one in-person visit with a DEA-registered practitioner before receiving a controlled-substance prescription via telemedicine, unless a qualifying exception applies. Hers does not prominently prescribe scheduled medications as a core product line, but mental health offerings (including some stimulants or benzodiazepines) fall under these rules. Patients should confirm whether their specific prescriber meets DEA registration requirements for the state.

FDA Compliance and Compounded Medications

The FDA does not certify or accredit telehealth platforms. Its oversight applies to the drugs themselves. FDA-approved versions of semaglutide (Ozempic, Wegovy) are legal when prescribed by a licensed clinician. Compounded semaglutide occupied a contested gray zone for much of 2023-2024 because semaglutide was on the FDA drug shortage list, which allowed 503A and 503B compounding. The FDA removed semaglutide from the shortage list in early 2025, which restricts compounding of semaglutide going forward for most commercial compounders. Any Hers product labeled as "compounded semaglutide" after that removal date warrants extra scrutiny.

SEC Filings as a Transparency Signal

As a publicly traded company, Hims & Hers Health files 10-K annual reports and 10-Q quarterly reports with the SEC. These disclose legal proceedings, material regulatory risks, and business model changes. Reviewing the most recent 10-K gives a candid look at pending litigation or regulatory investigations that company-controlled marketing material will not mention.

BBB Rating, Complaints, and What They Reveal

The Better Business Bureau gives Hers (filed under Hims & Hers Health, Inc.) a B+ rating as of mid-2025, with more than 200 complaints closed in the preceding 36 months. That volume matters less than what the complaints describe.

Most Common Complaint Categories

Reviewing the BBB complaint summaries across the Hers platform, three patterns appear repeatedly.

Billing and subscription cancellation. The most common complaint type involves charges continuing after patients believe they have cancelled. Subscription-based telehealth models are prone to this problem because auto-refill and auto-renewal are on by default. Multiple complainants report difficulty reaching customer service to halt shipments or obtain refunds.

Prescription delays and fulfillment gaps. A second cluster involves patients paying for a consultation, receiving a prescription, and then waiting weeks for the medication without clear status updates. For time-sensitive treatments like antidepressants or hormone therapy, this gap creates real clinical risk, including discontinuation symptoms for patients stopping and restarting SSRIs.

Clinical quality concerns. A smaller but clinically significant subset of complaints describes feeling "rubber-stamped" through a consultation without adequate medical history review or follow-up. Asynchronous telehealth, where patients fill out a questionnaire and a clinician reviews it without a live call, carries inherent limits in detecting contraindications.

How to Read BBB Data Critically

BBB ratings reflect complaint volume and company responsiveness, not clinical outcomes. A platform with a high complaint volume but quick resolution scores better than one with fewer complaints that ignores them. The B+ rating means Hers responds to most complaints, not that complaints are rare or unwarranted. The BBB's own methodology page notes that accreditation and ratings are separate: Hers is not BBB-accredited, which means it has not paid for accreditation and has not agreed to BBB binding arbitration.

Clinical Services Offered and Evidence Quality

Hers covers four main therapeutic areas. Each carries a different evidence base and a different regulatory risk profile.

Hormone Replacement Therapy (HRT)

Hers offers oral estrogen, topical estrogen, vaginal estrogen, and progesterone for perimenopause and menopause. The 2022 Menopause Society (formerly NAMS) position statement supports hormone therapy for symptomatic menopause in appropriate candidates under 60 or within 10 years of menopause onset. Hers prescribers are expected to follow these guidelines, but asynchronous intake forms may not capture all contraindications (personal or family history of hormone-sensitive cancer, prior thromboembolism, uncontrolled hypertension) with the same depth as an in-person visit.

The Women's Health Initiative (WHI), the largest HRT trial to date (N=16,608), found that combined estrogen-progestin therapy was associated with a hazard ratio of 1.26 for breast cancer and 1.41 for stroke over 5.6 years of follow-up [1]. Those risks apply to oral combined HRT specifically and are lower for transdermal estrogen and progesterone, but a telehealth intake questionnaire must still screen for them.

GLP-1 Weight Loss Medications

Hers offers semaglutide-based weight management. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg subcutaneous weekly produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [2]. That is a meaningful clinical effect for the right patient. The concern with D2C platforms is appropriate patient selection: FDA labeling for Wegovy restricts use to adults with a BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity. Asynchronous intake may not adequately verify BMI or screen for personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, both labeled contraindications.

Mental Health

Hers prescribes SSRIs and SNRIs for depression and anxiety, as well as non-stimulant options for ADHD. The American Psychiatric Association's 2023 practice guideline for major depressive disorder recommends a full diagnostic interview and PHQ-9 scoring before initiating antidepressant therapy. Whether an asynchronous questionnaire constitutes a "full diagnostic interview" is a legitimate clinical question.

Patients starting SSRIs should have a plan for monitoring suicidality in the first 1-4 weeks, as required by the FDA's black box warning. An asynchronous platform with limited follow-up infrastructure may not provide adequate monitoring for high-risk patients.

Hair Loss

Hers prescribes topical minoxidil and spironolactone for female pattern hair loss. Both are well-supported by evidence and carry lower risk profiles than the other categories above. A 2019 Cochrane review found topical minoxidil superior to placebo for androgenetic alopecia, with an RR of 2.15 for achieving ≥50% hair regrowth at 32 weeks. This is the lowest-risk product category Hers offers from a clinical appropriateness standpoint.

How Hers Compares to URAC and NCQA Accreditation Standards

URAC and NCQA are the two major healthcare accreditation bodies in the United States. Neither has publicly listed Hers as an accredited telehealth organization as of July 2025. This is not unusual: most D2C telehealth startups have not pursued formal URAC or NCQA accreditation, which requires extensive documentation of clinical protocols, quality improvement programs, and patient safety audits.

The URAC telehealth accreditation program sets standards for provider credentialing, clinical guidelines adherence, and patient safety incident reporting. The absence of URAC accreditation does not make a telehealth platform illegal or unsafe, but it does mean no independent clinical auditor has reviewed its processes.

Patients who want a higher-assurance option for complex conditions (post-surgical HRT, multiple comorbidities, psychiatric diagnoses) may find a URAC- or NCQA-accredited telehealth provider a better fit than a platform whose quality processes have not been externally audited.

Hers Pricing, Subscription Model, and Transparency

Hers uses a subscription model with auto-refill. Prices for its core products range roughly from $25 to $299 per month depending on the medication and consultation type, but pricing is not always displayed upfront before a patient completes intake.

The FTC's guidelines on negative option marketing require clear disclosure of subscription terms and easy cancellation mechanisms. Several BBB complaints allege that cancellation required multiple steps or resulted in additional charges, a pattern the FTC specifically targets. Hers updated its cancellation flow in 2023 following regulatory attention to the D2C telehealth subscription model broadly.

Patients should confirm subscription terms, cancellation windows, and refund policies in writing (via the platform's terms of service) before completing any payment. Saving a screenshot of the subscription terms at enrollment is a practical protective step.

What Independent Patient Reviews Show

Beyond the BBB, patient reviews on Trustpilot and Reddit's r/Telehealth and r/WomensHealth communities reflect a bimodal distribution. Patients with straightforward conditions (mild hair thinning, stable mood disorders, early menopause symptoms with no contraindications) generally report a positive experience, citing convenience and cost savings compared to in-person care.

Patients with more complex presentations report frustration with the limits of asynchronous care. Common issues include receiving a prescription without any explanation of why an alternative was chosen, no follow-up after starting a new medication, and difficulty escalating concerns to a supervising physician versus a customer service representative.

The American Telemedicine Association's practice guidelines note that telehealth is appropriate for established diagnoses and routine medication management, but that new-onset or complex conditions generally warrant a synchronous visit with full history-taking. Hers offers both synchronous and asynchronous options; patients with complex histories should request a live video visit rather than relying solely on the intake questionnaire.

Red Flags to Watch and Green Lights That Indicate Safety

Not all concerns about Hers rise to the level of red flags, and not all positives are equally meaningful. Here is a grounded framework for evaluating what the accreditation record actually tells you.

Legitimate Safety Signals

• LegitScript certification confirms legal pharmacy operations and prescription-before-dispensing compliance.
• Public company status means audited financials and SEC disclosure of material legal risk.
• State licensure of providers is required before prescribing in any state.
• FDA-approved drugs (not just compounded versions) are available in Hers' formulary.

Areas Requiring Personal Due Diligence

• Compounded semaglutide availability post-shortage-list removal should be verified given the FDA's 2025 rule changes.
• Asynchronous consultation for HRT or mental health in patients with complex histories warrants a follow-up synchronous visit.
• Subscription auto-renewal terms should be reviewed and saved before payment.
• URAC/NCQA accreditation is absent, meaning no external clinical audit of protocols.

Absolute Contraindications to Async-Only Care

Patients with a history of hormone-sensitive cancer, prior venous thromboembolism, active suicidality, or multiple endocrine neoplasia should not rely on an asynchronous intake questionnaire as their only clinical evaluation. These presentations require a clinician who can ask follow-up questions in real time.

Clinician Perspective on Hers' Model

"Telehealth platforms like Hers can genuinely expand access for patients who cannot get a timely in-person appointment for something like topical minoxidil or a low-dose SSRI," says a board-certified internist on the HealthRX medical team. "The concern is when a patient with three comorbidities and a complex medication list gets the same asynchronous intake form as someone who is otherwise healthy. The platform does not always triage those cases differently."

That framing aligns with guidance from the American College of Obstetricians and Gynecologists (ACOG), which states that telehealth is ethically appropriate when the modality matches the complexity of the clinical situation and when follow-up care is accessible.